In phenotypic screening for adiponectin-production enhancing compounds with therapeutic potentials in various metabolic diseases, butyrolactone I significantly enhanced adiponectin production in non-cytotoxic concentrations. Here, ADIPOQ is linked to Other metabolic disease.